Loading...
OTCM
DNDT
, Last price  
USD
Name

DND Technologies Inc

Chart & performance

D1W1MN
OTCM:DNDT chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
160.39%
Rev. 5Y
-63.93%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
05,371,9338,736,52615,799,91613,753,7257,090,98270,44377,240000
Net income
-50k
L-2.89%
-146,213-1,460,477-2,736,2581,235,022-4,560,362-1,892,85056,79756,290-76,660-50,971-49,500
CFO
17k
P
-173,860-508,878-77,486917,085-172,764288,786-9,40016,900

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in New York City, DND Technologies, Inc. was established in 1997. Operating as a holding company, DND Technologies specializes in the production and sale of diverse specialty balms. Beyond balms, the company is a key manufacturer and distributor of pharmaceutical goods. Its portfolio includes Bioassaygen Gel, formulated to diminish wrinkles and promote natural skin regeneration. The Bioassaygen Cosmetic Mask serves aesthetic enhancement purposes. Additionally, DND offers Bioassaygen Bio-Skin, an innovative skin replacement bandage, and Bioassaygen Delivery Gel, designed to accelerate natural skin renewal. These products reach consumers and businesses through a multi-channel distribution strategy, encompassing wholesale, retail outlets, and e-commerce platforms.
IPO date
May 15, 2002
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFY
2025‑122024‑122023‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT